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Abstract
Voltage-gated potassium channels (Kv) are important regulators of membrane potential in
vascular smooth muscle cells, which is integral to controlling intracellular Ca2+ concentra-
tion and regulating vascular tone. Previous work indicates that Kv channels can be modulat-
ed by receptor-driven alterations of cyclic AMP-dependent protein kinase (PKA) activity.
Here, we demonstrate that Kv channel activity is maintained by tonic activity of PKA. Whole-
cell recording was used to assess the effect of manipulating PKA signalling on Kv and ATP-
dependent K+ channels of rat mesenteric artery smooth muscle cells. Application of PKA
inhibitors, KT5720 or H89, caused a significant inhibition of Kv currents. Tonic PKA-
mediated activation of Kv appears maximal as application of isoprenaline (a β-adrenoceptor
agonist) or dibutyryl-cAMP failed to enhance Kv currents. We also show that this modulation
of Kv by PKA can be reversed by protein phosphatase 2B/calcineurin (PP2B). PKA-
dependent inhibition of Kv by KT5720 can be abrogated by pre-treatment with the PP2B in-
hibitor cyclosporin A, or inclusion of a PP2B auto-inhibitory peptide in the pipette solution.
Finally, we demonstrate that tonic PKA-mediated modulation of Kv requires intact caveolae.
Pre-treatment of the cells with methyl-β-cyclodextrin to deplete cellular cholesterol, or add-
ing caveolin-scaffolding domain peptide to the pipette solution to disrupt caveolae-
dependent signalling each attenuated PKA-mediated modulation of the Kv current. These
findings highlight a novel, caveolae-dependent, tonic modulatory role of PKA on Kv chan-
nels providing new insight into mechanisms and the potential for pharmacological manipula-
tion of vascular tone.
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Introduction
K+ channels play an important role in regulating the membrane potential of vascular
smooth muscle cells. Activation of K+ channels results in hyperpolarization, a decrease in
[Ca2+]i and vasodilation, while their inhibition leads to depolarization, an increase in
[Ca2 +]i and vasoconstriction [1]. Several types of K
+ channels are expressed in arterial
smooth muscle, including ATP-dependent K+ (KATP) channels, inward-rectifier K
+ chan-
nels, large-conductance, Ca2+-activated K+ (BKCa) channels and voltage-gated K
+ (Kv)
channels, and all are involved in regulating the membrane potential [1–4]. K+ channel mod-
ulation via intracellular signalling pathways is well established [1,5]. We and others have
shown that the vasoconstrictors angiotensin II (Ang-II) and endothelin-1 (ET-1) inhibit
both KATP and Kv currents of rat mesenteric artery smooth muscle (MASMC), through acti-
vation of PKC [6,7] [8–10]. In addition to the PKC pathway, inhibition of cyclic AMP-
dependent protein kinase (PKA) has also been shown to be a component of the attenuation
of KATP and Kv current of mesenteric smooth muscle by Ang-II, suggesting a certain level of
tonic activation of K+ channels by PKA [7,8]. Moreover, Kv channel activity recorded in
inside-out patches of mesenteric artery smooth muscle cells is increased following applica-
tion of the catalytic subunit of PKA [8].
Vasodilator-mediated activation of GPCRs, such as β-adrenoceptors, can lead to Gαs-
mediated adenylyl cyclase (AC) activation, cAMP production and activation of PKA, leading
to hyperpolarization and vasodilation. PKA-dependent enhancements of BKCa and KATP cur-
rents in pig coronary arteries by calcitonin gene-related peptide [11,12], of KATP current in
mesenteric arterial smooth muscle cells by vasoactive intestinal polypeptide [13], and in rabbit
portal vein and rat aortic smooth muscle by the β-adrenoceptor agonist isoprenaline [14,15]
have been reported. Interestingly, however, application of agents that directly (dibutyryl-
cAMP) or indirectly (forskolin) activate PKA have been shown not to enhance Kv currents in
isolated cerebral arterial smooth muscle cells [16].
Targeting of PKA to ion channels (or associated regulatory proteins) has, in many cases,
been shown to involve PKA-anchoring proteins (AKAPs) and caveolae [17,18]. AKAPs operate
via a specialized anchoring domain that localizes the PKA-AKAP complex to specific intracel-
lular locations to facilitate PKA-mediated phosphorylation [19,20]. In contrast, caveolae are in-
vaginations that form in cholesterol- and sphingolipid-rich membrane microdomains that can
be distinguished from lipid rafts by the presence of the cholesterol binding protein caveolin
[18,21,22]. Signalling complexes are co-localized within these microdomains, presumably facil-
itating the correct targeting of signalling events [18]. Caveolin-1 and PKA have been shown to
co-localize in cultured AV12 cells [23] and disruption of caveolae by cholesterol depletion un-
couples AC-dependent regulation of KATP channels in vascular smooth muscle [24]. Further-
more, KATP channels expressed in HEK293 cells are inhibited, either by caveolin-1 co-
expression, or by inclusion of caveolin-1 scaffolding domain peptide (CSDP) in the patch
pipette [25].
Vasodilator-driven modulation of K+ channels via PKA signalling complexes and
the role of tonic activation of PKA is poorly understood. Important yet to be defined
aspects of tonic PKA modulation are, (i) how the catalytic PKA subunits are targeted to
voltage-gated K+ channels, and (ii) what is responsible for reversing the PKA effects. In this
study we have focused on investigating the extent of tonic PKA signalling and the potential
targeting mechanisms for the PKA-induced activation of the voltage-gated K+ current
in these cells. We have determined that PP2B is responsible for reversing this action of
PKA and have examined the roles of AKAPs and caveolae in targeting PKA signalling to
these channels.
PKA/PP2B Modulation of Kv Channels
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Materials and Methods
Animals
All experiments were carried out on adult male Wistar rats (200–300 g) killed by cervical dislo-
cation. The care of animals was in accordance with the UK Animals (scientific procedures) Act
1986. Investigations carried out in this study conformed to the Guide for the Care and use of
laboratory animals published by the US National Institutes of Health (NIH publications
No. 85–23 revised 1996). The procedures used in this study were approved by the University of
Leicester Animal Care and Use Committee.
Cell Isolation
Rat mesenteric arteries were dissected and placed in cold zero-Ca2+ solution containing (in
mM): 5.4 KCl, 137 NaCl, 0.44 Na2HPO4, 0.42 NaH2PO4, 4 glucose, 6 mannitol, 10 HEPES and
1 MgCl2, adjusted to pH 7.4 with NaOH. A two-stage enzymatic digestion was then carried out
at 35°C as described previously [8]. Briefly, the tissue was placed in a low-Ca2+ solution (the so-
lution above with 0.1 mM CaCl2 added) containing 0.9 mg mL
-1 albumin, 2.0 mg mL-1 papain
and 2.0 mg mL-1 dithioerythritol for 31 min. Following this, mesenteric arteries were digested
for a further 12.5 min in low-Ca2+ solution containing 1.1 mg mL-1 collagenase type F and 1.3
mg mL-1 hyaluronidase. The digested tissue was triturated gently to yield isolated smooth mus-
cle cells. After isolation, cells were stored on ice in low-Ca2+ solution containing 1 mM sodium
pyruvate for use on the same day.
Electrophysiology
K+ currents were recorded from isolated smooth muscle cells using the conventional whole-cell
patch clamp technique. This enabled intracellular access of membrane impermeant inhibitory
peptides by their inclusion in the patch pipette. Patch pipettes (resistance 4–6 MΩ when filled)
were made from filamented borosilicate glass (outer diameter 1.5 mm, inner diameter 0.86
mm; Harvard Apparatus) using a Narishige PC-10 pipette puller. Currents were recorded
using an Axopatch 200A amplifier (Molecular Devices, Sunnyvale, CA, USA), filtered at 2 kHz
and sampled at 10 kHz using a Digidata 1322A interface (Molecular Devices, Sunnyvale, CA,
USA). Kv currents were activated by 400 ms voltage pulses to potentials ranging from -40 to
+60 mV from a holding potential of -65 mV. A P/6 protocol was used to remove leak and ca-
pacitive currents. The intracellular solution contained (in mM): 110 KCl, 30 KOH, 10 Hepes,
10 EGTA, 1 MgCl2, 3.9 CaCl2, 1 Na2ATP, 0.1 ADP and 0.5 GTP adjusted to pH 7.2 with
NaOH. The free [Ca2+], calculated using Maxchelator (http://www.stanford.edu/%7Ecpatton/
maxc.html), was 100 nM. The concentrations of ATP, ADP and GTP used in the pipette were
designed to give optimal activity of KATP channels whilst maintaining adequate signalling com-
ponents. The external solution contained (in mM): 6 KCl, 134 NaCl, 4 glucose, 6 mannitol, 10
Hepes, 1 MgCl2 and 0.1 CaCl2, adjusted to pH 7.4 with NaOH. To minimize contamination
from BKCa channel activity currents were recorded in the presence of 100 nM penitrem A,
which virtually abolishes BKCa current at this concentration [26,27]. All experiments were car-
ried out only after Kv currents became stable after establishing whole-cell recording [8]. Unless
stated otherwise, all patch-clamp experiments were done at 30–32°C, maintained using a
Dagan HW-30 temperature controller.
Recordings were analysed using pCLAMP (Molecular Devices, Sunnyvale, CA, USA) and
Excel (Microsoft) software. Current-voltage curves were obtained by averaging the current be-
tween 320 and 370 ms of the test pulse and plotted either as current density (normalized to the
PKA/PP2B Modulation of Kv Channels
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cell capacitance) or normalized to the current value obtained at +40 or +60 mV under the ap-
propriate control conditions.
Materials
Caveolin scaffolding domain peptide and its scrambled version were obtained from Merck Bio-
sciences (Nottingham, UK), calcineurin auto-inhibitory peptide was from Enzo Life Science
(Exeter, UK), KT 5720 and 2’,5’-dideoxyadenosine were from Tocris (Bristol, UK) and PKA in-
hibitory peptide (PKI-RR, CTTYADFIASGRTGRRNAIHD) and its inactive analogue PKAi-
AA were from Pepceuticals (Leicester, UK). All other chemicals and reagents were purchased
from Sigma-Aldrich (Poole, UK).
Data Analysis and Statistics
Data are presented throughout as means ± s.e.m. Statistical significance was assessed using Stu-
dent’s paired t-test, one-way ANOVA or two-way ANOVA with Bonferroni’s post hoc test as
appropriate. A value of P<0.05 was considered significant. All statistical analysis was carried
out using GraphPad Prism (San Diego, CA, USA).
Results
Whole-cell patch clamp recordings from rat MASMC revealed Kv currents activated in re-
sponse to depolarizing voltage steps to potentials more positive than about -30mV (e.g. Fig. 1).
These currents activated relatively slowly and displayed little inactivation during the 400 ms
pulses. We found that Kv current density (normalized to cell capacitance) was variable in
MASMC; and for this reason we have assessed the effects of pharmacological manipulation of
Kv currents as a fraction of the currents recorded under the appropriate control conditions.
Steady-state activation of Kv current by PKA
We have shown previously that a component of the Ang-II-induced inhibition of Kv current in
rat MASMC occurs through a reduction in PKA activity [8]. To establish the level of tonic
PKA activation, which would dictate the relative importance of this pathway for the regulation
of Kv channel activity in these cells, we measured Kv current amplitudes before and after bath
application of the PKA inhibitor KT 5720. As shown in Fig. 1A, the amplitude of the Kv cur-
rent, measured over a range of voltages, was reduced following 10–15 min exposure to 1 μM
KT 5720, indicating that under our control conditions there was considerable tonic PKA acti-
vation of Kv channels. Current values were normalized to the control current obtained at +60
mV for each cell and mean normalized I-V relationships are shown in Fig. 1B (n = 8). At +60
mV Kv current decreased to 65 ± 5% of control values following the application of KT 5720
(P<0.05, n = 8). A similar inhibition was found with another membrane permeable PKA inhib-
itor H-89 (1 μM), which decreased the current at +60 mV to 63 ± 8% of control values
(P<0.05; n = 5). To test whether KT 5720 was blocking the current through a mechanism inde-
pendent of PKA, a PKA inhibitory peptide (PKAi-RR; 5 μM) was included in the patch pipette
and inhibition of the Kv current by KT 5720 was assessed. Mean Kv current densities at +60
mV, measured approximately 3 minutes following the establishment of whole-cell configura-
tions, were 30.9 ± 3.8 (n = 13) and 21.8 ± 2.2 (n = 10) pA pF-1 in control and in PKAi-RR con-
taining pipette solutions respectively (this difference was not quite significant (P = 0.06),
though as stated above current densities were variable in these cells). Control Kv currents were
recorded 3 minutes after establishing whole-cell configurations; KT 5720 was then applied and
its effect on the Kv current was assessed after 10–15 minutes. Application of KT 5720 to cells
PKA/PP2B Modulation of Kv Channels
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Fig 1. Inhibition of PKA attenuates Kv current. Kv currents were activated in response to 400 ms depolarizing voltage steps from a holding potential of -65
mV. (A) Representative Kv current traces before (control) and after application of 1 μMKT 5720 as indicated. Representative Kv currents shown in this and
subsequent figures are in 20 mV increments beginning from -40 mV. (B) Mean (± s.e.m.) I-V plots (normalized to control current at +60 mV) before and after
application of 1 μMKT 5720 (n = 8 cells). (C) Representative Kv current traces before and after application of 1 μMKT 5720 obtained in the presence of the
PKA inhibitor peptide, PKAi-RR (5 μM) in the patch pipette. (D) Mean (± s.e.m.) I-V plots (normalized to the control currents, i.e. in the presence of PKAi-RR,
at +60 mV) before and after application of 1 μMKT 5720 as indicated (n = 5). (E) Representative Kv current traces before and after application of 1 μMKT
5720 in the presence of PKAi-AA (5 μM), an inactive isoform of PKAi-RR, in the patch pipette. (F) Mean (± s.e.m.) I-V plots (normalized to the respective
control currents, i.e. in the presence of PKAi-AA at +60 mV) before and after application of 1 μMKT 5720 as indicated (n = 7). *P<0.05; two-way ANOVA,
Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0121285.g001
PKA/PP2B Modulation of Kv Channels
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recorded with PKAi-RR in the pipette no longer decreased the Kv current, which remained at
93 ± 8% of control current measured at +60 mV (n = 5). In contrast, KT 5720 remained effec-
tive when the pipette contained PKAi-AA, an inactive homologue of PKAi-RR; the Kv current
was decreased to 65 ± 10% (n = 7) of the control current at +60 mV. These results are consis-
tent with a mechanism whereby KT 5720 is reducing the Kv current by inhibiting PKA.
Since tonic activation of PKA is likely to rely on the continued production of cAMP by AC,
inhibition of AC would be anticipated to reduce PKA-dependent Kv channel activity. Inhibi-
tion of AC with 2’,5’-dideoxyadenosine (DDA) decreased the amplitude of the Kv currents re-
corded from MASMC (Fig. 2). Kv currents were measured before and 10–15 min after the
application of DDA (50 μM) and normalized I-V curves were obtained as described above
(Fig. 2B). Mean Kv current amplitude at +60 mV in the presence of DDA was 57.3 ± 2.9% of
control (P<0.05, n = 6), suggesting that under control conditions there is significant back-
ground activity of AC.
Activating AC failed to enhance Kv current amplitude
Increasing PKA activity by vasodilators has been shown to enhance several vascular K+ cur-
rents [28–30], including Kv channels in rabbit portal vein and rat coronary artery [14,31,32].
To assess whether the Kv current of rat MASMC could be enhanced via GPCR-linked vasodila-
tors we examined the effect of isoprenaline, a β-adrenoceptor agonist, on Kv current amplitude.
Application of isoprenaline (1 μM), a concentration known to cause a>20-fold increase in
cAMP in vascular smooth muscle cells [15] had little or no effect on the Kv currents recorded
fromMASMC (Fig. 3; n = 8). Little effect was observed even when isoprenaline was added to
Fig 2. The adenlylate cyclase inhibitor, dideoxyadenosine attenuates Kv current. (A) Representative Kv current traces before (control) and after
application of 50 μM 2’,5’-dideoxyadenosine (DDA). (B) Mean (± s.e.m.) I-V plots (normalized to control current at +60 mV) before (control) and after
application of DDA. *P<0.05; two-way ANOVA, Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0121285.g002
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cells pre-treated for 10 min with the phosphodiesterase inhibitor IBMX (300 μM; n = 5). The
lack of effect of isoprenaline on the Kv current was mirrored by an inability of 100 μM
dibutyryl-cAMP, a membrane-permeable analogue of cAMP, to increase the Kv current (Fig. 3;
n = 4). To check whether cAMP/PKA signalling was intact in our cells we examined whether
isoprenaline, which we have shown to activate AC and KATP current in these cells [15], was still
effective under our current recording conditions. KATP currents were recorded in symmetrical
140 mM K+ at -60 mV, which minimized contamination by Kv currents. In contrast to its lack
of effect on Kv currents, isoprenaline (100 nM) effectively increased the KATP current recorded
Fig 3. Activation of PKA does not increase Kv current. (A) Representative Kv current traces obtained before and after application of isoprenaline (1 μM)
as indicated. (B) Mean (± s.e.m.) I-V plots (normalized to control current at +40 mV) before and after application of isoprenaline (1 μM; n = 8). (C)
Representative Kv current traces as in panel A, but in the presence of IBMX (300 μM) before and after application of isoprenaline (1 μM). (D) Mean I-V plots
(normalized to the control current in IBMX at +40 mV) before and after application of isoprenaline in the presence of IBMX (n = 5). (E) Representative Kv
current traces before (control) and after application of dibutyryl-cAMP (db-cAMP; 100 μM). (F) Mean (± s.e.m.) I-V plots (normalized to the control current at
+40 mV) before and after application db-cAMP (100 μM; n = 4).
doi:10.1371/journal.pone.0121285.g003
PKA/PP2B Modulation of Kv Channels
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in these cells (n = 6). This increase in KATP current was dependent on PKA activation as indi-
cated by the lack of response to isoprenaline in recordings where the patch pipette contained
5 μM PKAi-RR (Fig. 4; n = 8). These results indicated that β-adrenoreceptor stimulation was
viable and able to stimulate PKA signalling to KATP channels in these experiments.
PKA-dependent modulation of Kv was reversed by protein phosphatase 2B
The reduction of Kv current following inhibition of PKA by KT 5720 reveals that the reversal
of tonic PKA activation is likely due to dephosphorylation; however, the identity of the phos-
phatase involved is not known. Blocking dephosphorylation should abolish the effect of inhib-
iting PKA, thereby removing the effect of KT 5720 on the Kv current. Protein phosphatases 2A
(PP2A) and 2B (PP2B, calcineurin) have been found in vascular smooth muscle cells [33] and
PP2B has been shown to be involved in regulation of vascular KATP channels [34]. To deter-
mine whether either of these protein phosphatases is involved in reversing the PKA-mediated
modulation of MASMC Kv current, we examined the ability of KT 5720 to attenuate the Kv
current in the presence of PP2A or PP2B inhibitors. Pre-treatment with the PP2A inhibitor
cantharidin (30 μM for 10 min) had no effect on the reduction of Kv current by KT 5720
(1 μM, Fig. 5A and B). In contrast, in cells either pre-treated with the PP2B inhibitor cyclospor-
in A (4 μM for 10 min), or where the pipette solution contained calcineurin auto-inhibitory
peptide (100 μM), KT 5720 no longer inhibited the Kv current (Fig. 5C and D; n = 5). These re-
sults indicate that PP2B, but not PP2A, is involved in reversing PKA-enhanced Kv current.
Fig 4. Isoprenaline activates KATP current in a PKA-dependent manner.Representative KATP current traces obtained at -60 mV in symmetrical 140 mM
K+ following the application of isoprenaline (100 nM) in the absence (A) or presence (B) of the active PKA inhibitor peptide (PKAi-RR, 5 μM) in the patch-
pipette. Arrows in this and subsequent figures indicate the point at which extracellular [K+] was increased from 6 to 140 mM. The current increase in response
to isoprenaline is indicated by the dashed lines and arrows. (C) Mean KATP current, (normalized to that in 140 mM K
+) following the application of 100 nM
isoprenaline in the absence (n = 6) or presence (n = 8) of PKAi-RR in the patch-pipette (*P<0.05; one-way ANOVA, Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0121285.g004
PKA/PP2B Modulation of Kv Channels
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Fig 5. Regulation of Kv current in MSMCs involves protein phosphatase 2B (PP2B), but not protein phosphatase 2A (PP2A). (A) Representative Kv
current traces obtained from a cell pre-treated with cantharadin (Can, 30 μM) for 10 min before and after application of KT 5720 (1 μM). (B) Mean (± s.e.m.)
I-V plots, normalized to current in the presence of cantharadin (30 μM) at +60 mV, before and after the application of KT 5720 (1 μM, n = 4, *P<0.05; two-way
ANOVA, Bonferroni’s post hoc test). (C) Representative Kv current traces obtained with PP2B/calcineurin auto-inhibitory peptide (CAP, 100 μM) in the patch
pipette before and after application of KT 5720 (1 μM). (D) Mean (± s.e.m.) I-V plots, normalized to current in the presence of CAP at +60 mV, before and after
application of KT 5720 (1 μM, n = 5). €Mean (± s.e.m.) current at +60 mV (normalized to respective controls) following application of 1 μMKT 5720 in cells
pre-treated with cantharadin (Can, 30 μM, n = 4), cyclosporin A (CsA, 4 μM, n = 7), or with CAP (100 μM; n = 5) in the pipette as indicated (*P<0.05; one-way
ANOVA, Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0121285.g005
PKA/PP2B Modulation of Kv Channels
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PKA-anchoring proteins (AKAPs) do not mediate PKA activation of Kv
currents
Localized PKA signalling is mediated by AKAP binding to the regulatory subunit of PKA [35],
and this interaction can be abolished by Ht-31, a peptide that inhibits all PKA-AKAP interac-
tions [36]. PKA dependent activation of KATP channels in MASMC by calcitonin gene-related
peptide or by db-cAMP has been shown to be disrupted by inclusion of Ht-31 in the patch pi-
pette [28]. We have shown already that there is considerable tonic PKA signalling maintaining
the activity of Kv channels in these cells. If this is reliant on a PKA-AKAP interaction, inclusion
of Ht-31 in the patch pipette should disrupt this, leading to a decline in Kv current following
the establishment of the whole-cell configuration. However, we found no decline in the Kv cur-
rent up to 10 min after the establishment of whole-cell configurations with Ht-31 (20 μM) in
the pipette (Fig. 6; n = 5). In contrast, Ht-31 (20 μM) prevented the enhancement of the KATP
current following application of isoprenaline (100 nM, see Fig. 6C and D). These data indicate
that the interaction between PKA and AKAP, which is necessary to enable PKA signalling to
KATP channels, may not be involved in PKA-mediated enhancement of Kv currents in
MASMC.
Caveolae are required for tonic PKA-mediated regulation of Kv current
Caveolae are membrane invaginations containing the cholesterol binding protein caveolin and
are essential for many signalling events [18]. Caveolae have been shown to be necessary for
PKA-dependent regulation of KATP channels in vascular smooth muscle [24,25], and disrup-
tion of the interaction between caveolin-1 and BKCa channels suppresses the K
+ current in
human myometrial smooth muscle cells [37]. We, therefore, investigated whether caveolae are
required for tonic PKA-mediated regulation of Kv channels in MSMC. Caveolae are rich in
cholesterol [21] and treatment with the cholesterol depleting agent methyl-β-cyclodextrin (2%;
MβCD) has been shown to disrupt caveolae [38,39]. We, therefore, treated MASMC with 2%
MβCD for 60 min prior to assessing the effect of KT 5720 on Kv currents (Fig. 7A; n = 5). In
parallel experiments cells not treated with MβCD responded to KT 5720 as we show elsewhere
(Fig. 1A). However, in cells pre-treated with MβCD, the Kv current was no longer inhibited by
KT 5720 (1 μM), indicating that cholesterol depletion (and therefore disruption of caveolae)
blocks PKA-dependent modulation of Kv current. Kv currents, prior to KT 5720 perfusion, in
untreated versus MβCD-treated cells were not significantly different.
Since cholesterol depletion targets all lipid microdomains, to examine specifically whether
caveolae were involved in PKA modulation of the Kv currents we used caveolin scaffolding do-
main peptide (CSDP) which has been shown to disrupt caveolin-1-containing complexes
[25,39]. Inclusion of CSDP (100 μM) in the pipette solution blocked KT 5720-induced inhibi-
tion of Kv current (Fig. 7C and D; n = 5). In contrast, KT 5720-mediated inhibition of Kv cur-
rent remained when a scrambled version of CSDP (CSDP-scr) was included in the pipette
(Fig. 7E and F; n = 6). These data indicate that caveolin-1 is essential for maintaining correct
PKA/PP2B signalling to Kv channels in MASMCs.
Discussion
In this investigation we examined the extent of PKA-dependent modulation of Kv channels in
MASMC. Tonic PKA-mediated activation was demonstrated by the reduction in Kv current
following application of two structurally distinct PKA inhibitors, although the reduction was
significant only at more depolarized potentials (see Fig. 1B). A reduction in current amplitude
following application of the AC inhibitor DDA provides further evidence supporting tonic
PKA/PP2B Modulation of Kv Channels
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PKA activation of Kv currents in these cells. We identified the protein phosphatase that op-
poses PKA phosphorylation as PP2B, since blocking PP2A with cantharidin had no effect on
the ability of the PKA inhibitor KT 5720 to reduce Kv currents whereas blocking PP2B, either
with cyclosporin A, or by including calcineurin inhibitory peptide in the patch pipette, ren-
dered the Kv current insensitive to KT 5720. Finally, our results indicate that caveolae are a nec-
essary component of the PKA/PP2B-dependent modulation of Kv in MASMC.
Many K+ channels of vascular smooth muscle, including Kv channels, are subject to modu-
lation by protein kinases [5]. We and others have shown that Kv channel activity in several
Fig 6. PKA activation of Kv currents remained following disruption of PKA-AKAP interactions. (A) Representative Kv current traces obtained
immediately after establishing whole-cell recording (< 1 min Ht-31) and 10 min following establishment of the whole-cell configuration with 20 μMHt-31 in the
patch pipette. (B) Mean (± s.e.m.) I-V plots (current density normalized to cell capacitance) immediately after establishing whole-cell recording and 10 min
after establishing whole cell configuration in the presence of Ht-31 (20 μM) in the patch pipette (n = 5). (C) Representative KATP current traces (normalized to
cell capacitance) following the application of 100 nM isoprenaline in the absence or presence of 20 μMHt-31 in the patch pipette; the current increase in
response to isoprenaline is indicated by the dashed lines and arrow. (D) Mean glibeclamide-sensitive current (normalized to cell capacitance) following
application of 100 nM isoprenaline in the absence or presence of 20 μMHt-31 (n = 8 and 5 cells, respectively; *P<0.05; one-way ANOVA, Bonferroni’s post
hoc test).
doi:10.1371/journal.pone.0121285.g006
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vascular beds is reduced by vasoconstrictor-induced activation of PKC [6,8,10]. In addition to
PKC activation, a component of the Ang-II-induced reduction of MASMC Kv current occurs
through inhibition of PKA [8]. Although the extent of tonic PKA activation was not examined,
Hayabuchi and colleagues did show direct activation of Kv channels following application of
catalytic subunits of PKA to excised patches [8], as has been reported also for patches excised
from rabbit portal vein myocytes [14]. Similarly, application of the β-adrenoceptor agonist iso-
prenaline to stimulate AC was shown to enhance the Kv current in rabbit portal vein in a PKA-
dependent manner [32]. Surprisingly, neither application of isoprenaline (even following the
Fig 7. Inhibition of Kv current by KT 5720 is abolished by disruption of caveolae. (A) Representative Kv currents following 60 min pre-treatment with 2%
methyl-β-cyclodextrin (MβCD) before and after application of 1 μMKT 5720. (B) Mean I-V plots (normalized to control current in the presence of MβCD at +60
mV), before and after application of 1 μMKT 5720 (n = 5). (C) Representative Kv currents in the presence of the caveolin scaffolding-domain peptide (CSDP,
100 μM) in the patch pipette, before and after application of KT 5720 (1 μM). (D) Mean I-V plots (normalized to the current at +60 mV in the presence of
CSDP) before and after application of 1 μMKT 5720 (n = 5). (E) Representative Kv currents in the presence of a scrambled version of the caveolin
scaffolding-domain peptide (CSDP-scr, 100 μM) in the patch pipette before and after application of KT 5720 (1 μM). (F) Mean I-V plots (normalized to the
current at +60 mV in the presence of CSDP-scr) before and after application of 1 μMKT 5720 (n = 6, *P<0.05; two-way ANOVA, Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0121285.g007
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inhibition of endogenous phosphodiesterase activity by IBMX) nor direct activation of PKA by
db-cAMP was able to increase Kv currents of rat MASMC in our investigations. Comparable to
our findings, application of forskolin or db-cAMP to rat cerebral artery cells revealed a similar
inability of PKA activation to enhance Kv currents [16]. Although Li et al. [31] observed an in-
crease in K+ currents in response to isoprenaline in coronary SMCs, the currents measured in-
cluded BKCa activity and therefore do not definitively demonstrate an enhancement of Kv
current. To confirm the viability of PKA signalling in our cells we examined the effect of iso-
prenaline on the KATP current. An increase in KATP current following receptor-linked activa-
tion of AC, has been shown previously in rat MASMCs exposed to calcitonin gene-related
peptide [28] or isoprenaline [15], and in pig coronary arteries exposed to adenosine [40]. We
also observed an increase in KATP current following application of isoprenaline to MASMC,
which did not occur when PKAi-RR was in the pipette, demonstrating functioning PKA signal-
ling to KATP channels in our cells. We can therefore conclude that the absence of any enhance-
ment of Kv current in response to isoprenaline (or other cAMP-elevating manipulations)
reflects an insensitivity of this channel to further AC/PKA activation.
Previous work has shown that neuronal Kv2.1 channels can be dephosphorylated by calci-
neurin [41], and ceramide which inhibits Kv currents in pulmonary and mesenteric arteries
[42], has been shown to activate protein phosphatase 2A [43]. These findings suggest that Kv
channels could be modulated by PP2A and PP2B. Here we show that the protein phosphatase
involved is PP2B, since blocking PP2A with cantharidin had no effect on the ability of KT 5720
to reduce Kv currents, while blocking PP2B, either with cyclosporin A, or by inclusion of calci-
neurin inhibitory peptide in the patch pipette, rendered the Kv current insensitive to KT 5720.
Indeed, an opposing regulation of ion channels by PKA and calcineurin has been previously es-
tablished in other systems. For example, Santana et al. [44] showed that modulation of calcium
channels in cardiac myocytes was mediated via PKA and calcineurin. L-type Ca2+ channels in
L6 myocytes are inhibited by PKCα induced phosphorylation; however, a slight increase in in-
tracellular [Ca2+] removed this inhibition which was restored by blocking PP2B [45]. These au-
thors proposed that a low and maintained release of Ca2+ from intracellular stores activated
PP2B which reversed the PKC induced phosphorylation. Interestingly, KATP channel modula-
tion in both aortic smooth muscle and a heterologous expression system occurs via PP2B
[34,46]. It would, therefore, be interesting to investigate whether there is a common mecha-
nism for dephosphorylation of steady-state activation of both Kv and KATP in vascular smooth
muscle via PP2B. However, the balance between phosphorylation and dephosphorylation is
likely to reflect more complex interactions, as a similar experimental approach used by Mason
et al. [47] revealed that PKA-activated Kv1.5 channels expressed in Xenopus oocytes were de-
phosphorylated by a protein tyrosine phosphatase and not PP2A or PP2B. Also both PKA and
PP2B have been shown to bind to AKAP79, though at different sites [48,49]. If PP2B interacts
with AKAPs in our preparation, it is possible that disrupting AKAP function with Ht-31re-
stricts PP2B induced dephosphorylation. Thus, the regulation of Kv channel phosphorylation
and dephosphorylation revealed in this study may reflect only an aspect of the intracellular sig-
nalling between PKA, PP2B and Kv channels.
Both caveolae and AKAPs are necessary to direct PKA signalling to vascular KATP channels.
The AKAP inhibitor Ht-31 effectively uncouples steady-state PKA activation of KATP channels
in rat MASMC demonstrating that AKAPs are necessary to maintain PKA signalling to KATP
channels in these cells [24,28]. In contrast to the effects on KATP current, we found that Ht-31
peptide had little effect on the ability of KT 5720 to attenuate Kv current, suggesting that
steady-state PKA activation of MASMC Kv channels is not dependent on AKAPs. A potential
drawback to disrupting AKAP-PKA complexes is a general increase in cytosolic PKA and po-
tentially a resultant abnormal PKA-driven phosphorylation of substrates [35]. A recent report
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has indicated that the scaffolding protein PSD95 is necessary for PKA signalling to Kv1.2 chan-
nels in rat cerebral arteries [50] and it would be interesting to test whether this scaffolding pro-
tein too has a role in targeting PKA phosphorylation of Kv channels in MASMC. However,
cholesterol depletion, which is known to disrupt caveolae [39], rendered the Kv current insensi-
tive to KT 5720, suggesting that intact caveolae are necessary to maintain proper PKA and/or
PP2B targeting to Kv channels in our cells. Caveolae are identified by the presence of the cho-
lesterol binding protein caveolin, the scaffolding domain of which interacts with many
caveolae-associated channel proteins [18]. We found that inclusion of CSDP [51] in the pipette
disrupted the ability of KT 5720 to reduce Kv current amplitude, consistent with a mechanism
where interaction of Kv channels and PKA require intact caveolae. Co-expression of caveolin-1
and PKA led to a punctate co-localization, while expression of PKA alone resulted in a diffuse
expression of PKA [23]. Kv1.5 channels have been shown to interact with caveolin-1 to form a
signalling complex with 5-HT receptors in pulmonary artery smooth muscle [52] and specific
trafficking of Kv1.5 subunits to cholesterol-rich membrane domains requires caveolin [38].
These findings, along with the observations presented here, suggest that caveolar localization is
crucial for the physiological regulation of Kv channel activity.
In conclusion, our results show that there is a tonic PKA activation of Kv currents in rat
MASMC which is reversed by the action of PP2B. This signalling is dependent on the presence
of functional caveolae and on an interaction with caveolin-1. Activation of AC with isoprena-
line, or direct activation of PKA by db-cAMP, did not increase Kv current further. This suggests
that the amount of PKA-induced phosphorylation leading to Kv channel activation is maximal
and overcomes dephosphorylation by PP2B, which is revealed only in the presence of PKA in-
hibition. Alternatively, additional PKA activity induced by isoprenaline, which causes a PKA-
dependent increase of KATP current, may not be targeted to enhance Kv current. A precedent
for such targeting of signalling pathways to Kv channel modulation in MASMCs is provided by
work with ET-1 and Ang II [10,53]. While both vasoconstrictors activate PKCα and PKCε [53]
inhibition of Kv current by ET-1 occurs only through PKCα, while Ang II-mediated inhibition
occurs only through PKCε. The evidence presented in the present study indicates that AC/
PKA-mediated signalling to Kv channels is also tightly regulated. The subunit composition of
Kv channels within vascular smooth muscle is complex, and pharmacological and biophysical
evidence suggests that the Kv current is a composite passing through channels comprising dif-
ferent homo- or heteromultimers [54]. Varying expressions of several Kvα subunits (including
Kv1.2, 1.3, 1.5, 2.1 and Kv7.1–7.5) and Kvß subunits (Kvß1.1, 1.2 and 1.3) have been detected in
smooth muscle from different vascular beds [55, 56–58]. We focused our current study on as-
sessing the level of tonic PKA activation of the overall Kv current and on identifying the protein
phosphatase involved in reversing this effect. Future experiments shall focus on identifying the
relative role of PKA phosphorylation of specific subunits should enhance our understanding of
Kv channel modulation by PKA. Given the central role played by Kv in regulating myogenic
tone steady-state modulation of Kv by PKA is likely to play a pivotal role in determining blood
flow and pressure in the resistance vasculature [50,55].
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